{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:18:31Z","timestamp":1783099111035,"version":"3.54.6"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["440410\/2022-3"],"award-info":[{"award-number":["440410\/2022-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["444294\/2023-6"],"award-info":[{"award-number":["444294\/2023-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005667","name":"Foundation for Research Support and Innovation of Santa Catarina State","doi-asserted-by":"publisher","award":["2024TR002708"],"award-info":[{"award-number":["2024TR002708"]}],"id":[{"id":"10.13039\/501100005667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005667","name":"Foundation for Research Support and Innovation of Santa Catarina State","doi-asserted-by":"publisher","award":["2021TR000310"],"award-info":[{"award-number":["2021TR000310"]}],"id":[{"id":"10.13039\/501100005667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Redox Biology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.redox.2025.103889","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:44:27Z","timestamp":1760078667000},"page":"103889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Heterogeneous expression of immunotherapy response markers in non-small cell lung cancer with hyperactive NRF2 pathway: PD-L1 and beyond"],"prefix":"10.1016","volume":"87","author":[{"given":"Karoline","family":"Almeida-Lima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Falchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Delgobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros\u00e2ngela Mayer","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nauana","family":"Somensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Souza","family":"Zancanaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan N\u00f3brega","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Nascimento","family":"das Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisl\u00e9ia","family":"Golfetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danusa","family":"Leidens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Augustin","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicklas","family":"Bassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander James Roy","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella Serafin Couto","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassiano Mateus","family":"Forcelini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4188-3095","authenticated-orcid":false,"given":"Alfeu","family":"Zanotto-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.redox.2025.103889_bib1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.freeradbiomed.2021.10.020","article-title":"Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer","volume":"177","author":"Delgobo","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.redox.2025.103889_bib2","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.jtho.2019.08.005","article-title":"Mutations in the antioxidant KEAP1\/NRF2 pathway define an aggressive subset of NSCLC resistant to conventional treatments","volume":"14","author":"Nadal","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib3","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1158\/1078-0432.CCR-09-3352","article-title":"Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features","volume":"16","author":"Solis","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib4","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1158\/1078-0432.CCR-20-1985","article-title":"NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes","volume":"27","author":"Singh","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib5","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-17-3416","article-title":"Clinical and pathological characteristics of KEAP1- and NFE2L2-Mutated Non-Small cell lung carcinoma (NSCLC)","volume":"24","author":"Frank","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib6","doi-asserted-by":"crossref","first-page":"69847","DOI":"10.18632\/oncotarget.19349","article-title":"NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer","volume":"8","author":"Namani","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.redox.2025.103889_bib7","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1634\/theoncologist.2019-0885","article-title":"NFE2L2\/KEAP1 mutations correlate with higher tumor mutational burden Value\/PD-L1 expression and potentiate improved clinical outcome with immunotherapy","volume":"25","author":"Xu","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.redox.2025.103889_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2021.02.010","article-title":"Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab","volume":"154","author":"Shang","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.redox.2025.103889_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000706","article-title":"STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort","volume":"5","author":"Papillon-Cavanagh","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.redox.2025.103889_bib10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2022.06.010","article-title":"STK11 and KEAP1 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value among hispanics (STRIKE registry-CLICaP)","volume":"170","author":"Cordeiro de Lima","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.redox.2025.103889_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.21037\/atm.2019.11.52","article-title":"Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes","volume":"8","author":"Chen","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.redox.2025.103889_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cllc.2022.05.008","article-title":"Survival outcomes and treatment patterns in patients with NFE2L2 and\/or KEAP1 mutation-positive advanced squamous cell NSCLC using a real-world clinico-genomic database","volume":"23","author":"Wu","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.redox.2025.103889_bib13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed Death-(Ligand)1 inhibition in STK11- and KEAP1-Mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-19-1237","article-title":"Role of KEAp1\/NFE2L2 mutations in the chemotherapeutic response of patients with non\u2013small cell lung cancer","volume":"26","author":"Jeong","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib16","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jtho.2019.07.003","article-title":"Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma","volume":"14","author":"Goeman","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.redox.2025.103889_bib18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"The cancer genome atlas research network, Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.redox.2025.103889_bib19","doi-asserted-by":"crossref","first-page":"13568","DOI":"10.1073\/pnas.0806268105","article-title":"Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy","volume":"105","author":"Shibata","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.redox.2025.103889_bib20","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1371\/journal.pmed.0030420","article-title":"Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer","volume":"3","author":"Singh","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.redox.2025.103889_bib21","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/1873-3468.14458","article-title":"Genetic, metabolic and immunological features of cancers with NRF2 addiction","volume":"596","author":"Kitamura","year":"2022","journal-title":"FEBS Lett."},{"key":"10.1016\/j.redox.2025.103889_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.redox.2018.07.026","article-title":"A distinct class of antioxidant response elements is consistently activated in tumors with NRF2 mutations","volume":"19","author":"Levings","year":"2018","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2025.103889_bib23","doi-asserted-by":"crossref","first-page":"7416","DOI":"10.1093\/nar\/gks409","article-title":"Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha","volume":"40","author":"Chorley","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.redox.2025.103889_bib24","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1158\/1535-7163.MCT-16-0271","article-title":"Alkylating agent\u2013induced NRF2 blocks endoplasmic reticulum stress\u2013mediated apoptosis via control of glutathione pools and protein thiol homeostasis","volume":"15","author":"Zanotto-Filho","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.redox.2025.103889_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","article-title":"NRF2 and the hallmarks of cancer","volume":"34","author":"Rojo de la Vega","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.redox.2025.103889_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.106347","article-title":"Omics-based identification of an NRF2-related auranofin resistance signature in cancer: insights into drug repurposing","volume":"152","author":"Falchetti","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.redox.2025.103889_bib27","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","article-title":"PD-L1 expression in lung cancer","volume":"11","author":"Yu","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib28","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1131379","article-title":"PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations","volume":"5","author":"Scheel","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.redox.2025.103889_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1865670","article-title":"Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation","volume":"10","author":"Nie","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.redox.2025.103889_bib30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.redox.2025.103889_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.redox.2025.103889_bib32","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.redox.2025.103889_bib33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.redox.2025.103889_bib34","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1158\/1078-0432.CCR-19-3663","article-title":"Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non\u2013small cell lung cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6879","article-title":"Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis","author":"Yu","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.redox.2025.103889_bib36","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","article-title":"Immune-related gene expression profiling after PD-1 blockade in non\u2013small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma","volume":"77","author":"Prat","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib37","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.redox.2025.103889_bib38","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.annonc.2020.08.2105","article-title":"KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden","volume":"31","author":"Marinelli","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib39","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.jtho.2021.08.010","article-title":"KEAP1 and TP53 frame genomic, evolutionary, and immunologic subtypes of lung adenocarcinoma with different sensitivity to immunotherapy","volume":"16","author":"Scalera","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.annonc.2022.12.002","article-title":"Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma","volume":"34","author":"Scalera","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib41","article-title":"Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma","volume":"4","author":"Duan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.redox.2025.103889_bib42","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-023-03056-9","article-title":"Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomes","volume":"23","author":"Wang","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.redox.2025.103889_bib43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.annonc.2023.01.011","article-title":"Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC","volume":"34","author":"Mok","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib44","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmet.2018.02.006","article-title":"Synergy between the KEAP1\/NRF2 and PI3K pathways drives non-small-cell lung cancer with an altered immune microenvironment","volume":"27","author":"Best","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.redox.2025.103889_bib45","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.redox.2025.103889_bib46","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.jtho.2020.02.027","article-title":"KEAP1-NFE2L2\u2013Mutant NSCLC and immune checkpoint inhibitors: a large database analysis","volume":"15","author":"Zhang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib47","article-title":"KEAP1\/NFE2L2 mutations of liquid biopsy as prognostic biomarkers in patients with advanced non-small cell lung cancer: results from two multicenter, randomized clinical trials","volume":"11","author":"Zhu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2020.11.006","article-title":"PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab","volume":"151","author":"Wang","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.redox.2025.103889_bib49","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.08.011","article-title":"STK11\/LKB1 and KEAP1 mutations in non-small cell lung cancer: prognostic rather than predictive?","volume":"157","author":"Di Federico","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.redox.2025.103889_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003027","article-title":"Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS- mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial","volume":"10","author":"West","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.redox.2025.103889_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107510","article-title":"Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11\/KEAP1 comutations across PD-L1 levels","volume":"190","author":"Sun","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.redox.2025.103889_bib52","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-10778-6","article-title":"Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and\/or KEAP1 mutations in a real-world setting","volume":"23","author":"Julian","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.redox.2025.103889_bib53","doi-asserted-by":"crossref","first-page":"704","DOI":"10.7150\/thno.80184","article-title":"Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks","volume":"13","author":"Xu","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.redox.2025.103889_bib54","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/ijc.31975","article-title":"Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1\/NRF2-mutant lung cancer","volume":"144","author":"Cai","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.redox.2025.103889_bib55","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-23-4027","article-title":"Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer","volume":"30","author":"Van De Haar","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102904","article-title":"Immunoediting of KEAP1-NRF2 mutant tumours is required to circumvent NRF2-mediated immune surveillance","volume":"67","author":"Baird","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2025.103889_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102644","article-title":"A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies","volume":"61","author":"H\u00e4rk\u00f6nen","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2025.103889_bib58","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0762-1","article-title":"Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma","volume":"12","author":"Jiang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib59","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-Origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.redox.2025.103889_bib60","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","article-title":"TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data","volume":"44","author":"Colaprico","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.redox.2025.103889_bib61","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"Llya shmulevich, the immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.redox.2025.103889_bib62","doi-asserted-by":"crossref","first-page":"D1417","DOI":"10.1093\/nar\/gkac1006","article-title":"TIMEDB: tumor immune micro-environment cell composition database with automatic analysis and interactive visualization","volume":"51","author":"Wang","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.redox.2025.103889_bib63","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nbt.2203","article-title":"Absolute quantification of somatic DNA alterations in human cancer","volume":"30","author":"Carter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.redox.2025.103889_bib64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.redox.2025.103889_bib65","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","article-title":"A scaling normalization method for differential expression analysis of RNA-seq data","volume":"11","author":"Robinson","year":"2010","journal-title":"Genome Biol."},{"key":"10.1016\/j.redox.2025.103889_bib66","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the cancer cell line encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.redox.2025.103889_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05861-7","article-title":"Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogramming","volume":"9","author":"Olagnier","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.redox.2025.103889_bib68","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cell.2017.08.051","article-title":"Chemical proteomics identifies druggable vulnerabilities in a genetically defined cancer","volume":"171","author":"Bar-Peled","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.redox.2025.103889_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19593-0","article-title":"Enhancer remodeling promotes tumor-initiating activity in NRF2-activated non-small cell lung cancers","volume":"11","author":"Okazaki","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.redox.2025.103889_bib70","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.redox.2025.103889_bib71","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1158\/1078-0432.CCR-20-2790","article-title":"Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab \u00b1 Ipilimumab in gastric cancer\/gastroesophageal junction cancer A C","volume":"27","author":"Lei","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib72","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04705-3","article-title":"A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer","volume":"22","author":"Mason","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.redox.2025.103889_bib73","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.redox.2025.103889_bib74","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1158\/1078-0432.CCR-17-3451","article-title":"Interferon gamma messenger RNA signature in tumor biopsies predicts outcomes in patients with non\u2013small cell lung carcinoma or urothelial cancer treated with durvalumab","volume":"24","author":"Higgs","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib75","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.redox.2025.103889_bib76","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09840-6","article-title":"HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC","volume":"22","author":"Mei","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.redox.2025.103889_bib77","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib78","article-title":"Tumor-Infiltrating PD-1hiCD8+-T-Cell signature as an effective biomarker for immune checkpoint inhibitor therapy response across multiple cancers","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib79","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.redox.2025.103889_bib80","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.redox.2025.103889_bib81","doi-asserted-by":"crossref","first-page":"D1420","DOI":"10.1093\/nar\/gkaa1020","article-title":"TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment","volume":"49","author":"Sun","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.redox.2025.103889_bib82","series-title":"Bioinformatics for Cancer Immunotherapy: Methods and Protocols","first-page":"223","article-title":"An R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data","author":"F","year":"2020"},{"key":"10.1016\/j.redox.2025.103889_bib83","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.redox.2025.103889_bib84","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.redox.2025.103889_bib85","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.redox.2025.103889_bib86","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.1158\/0008-5472.CAN-18-3560","article-title":"Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods","volume":"79","author":"Jimenez-Sanchez","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib87","series-title":"Bioinformatics","first-page":"i436","article-title":"Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology","author":"Sturm","year":"2019"},{"key":"10.1016\/j.redox.2025.103889_bib88","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/jclinpath-2020-206832","article-title":"PD-L1 expression by tumor proportion score (TPS) and combined positive score (CPS) are similar in non-small cell lung cancer (NSCLC)","volume":"74","author":"De Marchi","year":"2021","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.redox.2025.103889_bib89","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","article-title":"Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas","volume":"31","author":"Schoenfeld","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib90","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jtho.2023.07.016","article-title":"KEAP1\/NFE2L2 pathway signature outperforms KEAP1\/NFE2L2 mutation status and reveals alternative pathway-activating mutations in NSCLC","volume":"18","author":"Arolt","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib91","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: recommendations by an International TILS working group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib92","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2020.10.017","article-title":"Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non\u2013small cell lung cancer treated with immunotherapy","volume":"145","author":"Gataa","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.redox.2025.103889_bib93","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s12253-019-00670-9","article-title":"The relationship between tumor-infiltrating lymphocytes, PD-L1 expression, driver mutations and clinical outcome parameters in non-small cell lung cancer adenocarcinoma in patients with a limited to no smoking history","volume":"26","author":"Mignon","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.redox.2025.103889_bib94","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nprot.2006.179","article-title":"Sulforhodamine B colorimetric assay for cytotoxicity screening","volume":"1","author":"Vichai","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.redox.2025.103889_bib95","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-022-02648-4","article-title":"Exaggerated false positives by popular differential expression methods when analyzing human population samples","volume":"23","author":"Li","year":"2022","journal-title":"Genome Biol."},{"key":"10.1016\/j.redox.2025.103889_bib96","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.redox.2025.103889_bib97","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2340154","article-title":"Redoxhigh phenotype mediated by KEAP1\/STK11\/SMARCA4\/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma","volume":"13","author":"Wei","year":"2024","journal-title":"OncoImmunology"},{"key":"10.1016\/j.redox.2025.103889_bib98","first-page":"101","article-title":"Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung","volume":"2","author":"Mendez","year":"2013","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9971","article-title":"Systematic pan-cancer analysis of tumour purity","volume":"6","author":"Aran","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.redox.2025.103889_bib100","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/0008-5472.CAN-16-2490","article-title":"Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment","volume":"77","author":"Varn","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib101","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-17-3416","article-title":"Clinical and pathological characteristics of KEAP1- and NFE2L2-mutated Non\u2013Small cell lung carcinoma (NSCLC)","volume":"24","author":"Frank","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.redox.2025.103889_bib102","author":"Lin"},{"key":"10.1016\/j.redox.2025.103889_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184562","article-title":"Pd-l1 dependent immunogenic landscape in hot lung adenocarcinomas identified by transcriptome analysis","volume":"13","author":"Kirfel","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.redox.2025.103889_bib104","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1038\/s41388-018-0314-0","article-title":"Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy","volume":"37","author":"Zhu","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.redox.2025.103889_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10050786","article-title":"Identification of a stable, non-canonically regulated nrf2 form in lung cancer cells","volume":"10","author":"Mikac","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.redox.2025.103889_bib106","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jtho.2021.08.764","article-title":"Comprehensive analysis of TP53 and KEAP1 mutations and their impact on survival in Localized- and advanced-stage NSCLC","volume":"17","author":"Saleh","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib107","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.jtho.2020.03.024","article-title":"KEAP1-NFE2L2 mutations in NSCLC: increased awareness needed. Reply to \u201cKEAP1-NFE2L2\u2013Mutant NSCLC and Immune Checkpoint Inhibitors: a Large Database Analysis,\u201d","volume":"15","author":"Mazzotta","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib108","article-title":"Neutrophil in the suppressed immune microenvironment: critical prognostic factor for lung adenocarcinoma patients with KEAP1 mutation","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Genet."},{"key":"10.1016\/j.redox.2025.103889_bib109","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1002\/cam4.4338","article-title":"Integrated analysis of patients with KEAP1\/NFE2L2\/CUL3 mutations in lung adenocarcinomas","volume":"10","author":"Jin","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.redox.2025.103889_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113295","article-title":"KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance","volume":"42","author":"Zavitsanou","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.redox.2025.103889_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1023833","article-title":"A signature-based classification of lung adenocarcinoma that stratifies tumor immunity","volume":"12","author":"Zhang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib112","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mdw436","article-title":"Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up","volume":"28","author":"Kadara","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib113","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.gendis.2022.10.009","article-title":"NRF2 participates in the suppressive tumor immune microenvironment of KRAS\/KEAP1 co-mutant non-small cell lung cancer by inhibiting the STING pathway","volume":"10","author":"Xiaodan","year":"2023","journal-title":"Genes Dis"},{"key":"10.1016\/j.redox.2025.103889_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102543","article-title":"Mutational activation of the NRF2 pathway upregulates kynureninase resulting in tumor immunosuppression and poor outcome in lung adenocarcinoma","volume":"14","author":"Fahrmann","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.redox.2025.103889_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102845","article-title":"A NRF2-induced secretory phenotype activates immune surveillance to remove irreparably damaged cells","volume":"66","author":"Baird","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.redox.2025.103889_bib116","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/ijc.25987","article-title":"Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth","volume":"129","author":"Tazzyman","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.redox.2025.103889_bib117","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11624","article-title":"Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription","volume":"7","author":"Kobayashi","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.redox.2025.103889_bib118","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.jtho.2021.10.016","article-title":"Survival analysis of TP53 comutations should be interpreted more cautiously","volume":"17","author":"Lin","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.redox.2025.103889_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107361","article-title":"Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (Co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C","volume":"184","author":"Boeschen","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.redox.2025.103889_bib120","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.redox.2025.103889_bib121","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.redox.2025.103889_bib122","article-title":"KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.redox.2025.103889_bib123","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41588-021-00778-2","article-title":"Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens","volume":"53","author":"Papalexi","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.redox.2025.103889_bib124","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","article-title":"Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer","volume":"55","author":"Ravi","year":"2023","journal-title":"Nat. Genet."}],"container-title":["Redox Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231725004021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231725004021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:02:10Z","timestamp":1773820930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213231725004021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":124,"alternative-id":["S2213231725004021"],"URL":"https:\/\/doi.org\/10.1016\/j.redox.2025.103889","relation":{},"ISSN":["2213-2317"],"issn-type":[{"value":"2213-2317","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneous expression of immunotherapy response markers in non-small cell lung cancer with hyperactive NRF2 pathway: PD-L1 and beyond","name":"articletitle","label":"Article Title"},{"value":"Redox Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.redox.2025.103889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103889"}}